These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 38394986)

  • 1. Identification of new risk factors for hydroxychloroquine and chloroquine retinopathy in systemic lupus erythematosus patients.
    Trefond L; Lhote R; Mathian A; de Chambrun MP; Pha M; Hie M; Miyara M; Papo M; Moyon Q; Taieb D; Saade S; Salem TB; Haroche J; Chasset F; Aubart FC; Zahr N; Amoura Z
    Semin Arthritis Rheum; 2024 Jun; 66():152417. PubMed ID: 38394986
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Retinal Complications in Patients with Systemic Lupus Erythematosus Treated with Antimalarial Drugs.
    Mukwikwi ER; Pineau CA; Vinet E; Clarke AE; Nashi E; Kalache F; Grenier LP; Bernatsky S
    J Rheumatol; 2020 Apr; 47(4):553-556. PubMed ID: 31474597
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk factors for hydroxychloroquine retinopathy in systemic lupus erythematosus: a case-control study with hydroxychloroquine blood-level analysis.
    Lenfant T; Salah S; Leroux G; Bousquet E; Le Guern V; Chasset F; Francès C; Morel N; Chezel J; Papo T; Cacoub P; Mouthon L; Guettrot-Imbert G; Cohen P; Régent A; Mauget-Faÿsse M; Piette JC; Jallouli M; Costedoat-Chalumeau N;
    Rheumatology (Oxford); 2020 Dec; 59(12):3807-3816. PubMed ID: 32442312
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases.
    Rainsford KD; Parke AL; Clifford-Rashotte M; Kean WF
    Inflammopharmacology; 2015 Oct; 23(5):231-69. PubMed ID: 26246395
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term effectiveness of antimalarial drugs in rheumatic diseases.
    Aviña-Zubieta JA; Galindo-Rodriguez G; Newman S; Suarez-Almazor ME; Russell AS
    Ann Rheum Dis; 1998 Oct; 57(10):582-7. PubMed ID: 9893568
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antimalarial drug toxicities in patients with cutaneous lupus and dermatomyositis: A retrospective cohort study.
    Mittal L; Zhang L; Feng R; Werth VP
    J Am Acad Dermatol; 2018 Jan; 78(1):100-106.e1. PubMed ID: 28989103
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Retinal toxicity in a multinational inception cohort of patients with systemic lupus on hydroxychloroquine.
    Almeida-Brasil CC; Hanly JG; Urowitz M; Clarke AE; Ruiz-Irastorza G; Gordon C; Ramsey-Goldman R; Petri MA; Ginzler EM; Wallace DJ; Bae SC; Romero-Diaz J; Dooley MA; Peschken C; Isenberg D; Rahman A; Manzi S; Jacobsen S; Lim SS; van Vollenhoven R; Nived O; Jönsen A; Kamen DL; Aranow C; Sánchez-Guerrero J; Gladman DD; Fortin PR; Alarcon GS; Merrill JT; Kalunian K; Ramos-Casals M; Steinsson K; Zoma A; Askanase AD; Khamashta M; Bruce IN; Inanc M; Lukusa L; Bernatsky S
    Lupus Sci Med; 2022 Nov; 9(1):. PubMed ID: 36396267
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discontinuation of antimalarial drugs in systemic lupus erythematosus.
    Wang C; Fortin PR; Li Y; Panaritis T; Gans M; Esdaile JM
    J Rheumatol; 1999 Apr; 26(4):808-15. PubMed ID: 10229401
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent findings about antimalarials in cutaneous lupus erythematosus: What dermatologists should know.
    Teboul A; Arnaud L; Chasset F
    J Dermatol; 2024 Jul; 51(7):895-903. PubMed ID: 38482997
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Skin and ophthalmic complications of chloroquine and hydroxychloroquine in patients with rheumatoid arthritis and systemic lupus erythematous.
    Zamani B; Hasan-Abad AM; Rafizadeh SM; Akbari H; Motedayyen H
    J Immunoassay Immunochem; 2024 May; 45(3):178-188. PubMed ID: 38722204
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Health status and concomitant prescription of immunosuppressants are risk factors for hydroxychloroquine non-adherence in systemic lupus patients with prolonged inactive disease.
    Iudici M; Pantano I; Fasano S; Pierro L; Charlier B; Pingeon M; Dal Piaz F; Filippelli A; Izzo V
    Lupus; 2018 Feb; 27(2):265-272. PubMed ID: 28659047
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The influence of obesity on hydroxychloroquine blood levels in lupus nephritis patients.
    Pedrosa T; Kupa LVK; Pasoto SG; Aikawa NE; Borba EF; Duarte NJ; Leon EP; Silva CA; Bonfá E
    Lupus; 2021 Apr; 30(4):554-559. PubMed ID: 33402039
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hydroxychloroquine and Chloroquine-Induced Cardiac Arrhythmias and Sudden Cardiac Death in Patients With Systemic Autoimmune Rheumatic Diseases: A Systematic Review and Meta-Analysis.
    Nikolic RPA; Virk MK; Buhler KA; Costenbader KH; Choi MY; Weber BN
    J Cardiovasc Pharmacol; 2024 Aug; 84(2):158-169. PubMed ID: 38922589
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early onset monocular hydroxychloroquine maculopathy in a systemic lupus erythematosus patient with history of central retinal artery occlusion: a case report.
    Ameen Ismail A; Sadek SH; Hatata RM
    BMC Ophthalmol; 2022 Nov; 22(1):434. PubMed ID: 36376841
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hydroxychloroquine in systemic lupus erythematosus (SLE).
    Ponticelli C; Moroni G
    Expert Opin Drug Saf; 2017 Mar; 16(3):411-419. PubMed ID: 27927040
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Critical Review of the Effects of Hydroxychloroquine and Chloroquine on the Eye.
    Costedoat-Chalumeau N; Dunogué B; Leroux G; Morel N; Jallouli M; Le Guern V; Piette JC; Brézin AP; Melles RB; Marmor MF
    Clin Rev Allergy Immunol; 2015 Dec; 49(3):317-26. PubMed ID: 25672591
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hydroxychloroquine daily dose, hydroxychloroquine blood levels and the risk of flares in patients with systemic lupus erythematosus.
    Fasano S; Messiniti V; Iudici M; Coscia MA; Ciccia F
    Lupus Sci Med; 2023 Jan; 10(1):. PubMed ID: 36631164
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hydroxychloroquine-induced pigmentation in patients with systemic lupus erythematosus: a case-control study.
    Jallouli M; Francès C; Piette JC; Huong du LT; Moguelet P; Factor C; Zahr N; Miyara M; Saadoun D; Mathian A; Haroche J; De Gennes C; Leroux G; Chapelon C; Wechsler B; Cacoub P; Amoura Z; Costedoat-Chalumeau N;
    JAMA Dermatol; 2013 Aug; 149(8):935-40. PubMed ID: 23824340
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hydroxychloroquine Blood Levels Predict Hydroxychloroquine Retinopathy.
    Petri M; Elkhalifa M; Li J; Magder LS; Goldman DW
    Arthritis Rheumatol; 2020 Mar; 72(3):448-453. PubMed ID: 31532077
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical impact of hydroxychloroquine dose adjustment according to the American Academy of Ophthalmology guidelines in systemic lupus erythematosus.
    Vázquez-Otero I; Medina-Cintrón N; Arroyo-Ávila M; González-Sepúlveda L; Vilá LM
    Lupus Sci Med; 2020 May; 7(1):. PubMed ID: 32434863
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.